Cargando…
P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011766/ http://dx.doi.org/10.1097/01.HS9.0000829656.69351.86 |
| _version_ | 1784687690475634688 |
|---|---|
| author | Rodríguez-Otero, P San-Miguel, J Anderson, LD Lonial, S Truppel-Hartmann, A Sanford, J Rowe, E Campbell, TB Munshi, N |
| author_facet | Rodríguez-Otero, P San-Miguel, J Anderson, LD Lonial, S Truppel-Hartmann, A Sanford, J Rowe, E Campbell, TB Munshi, N |
| author_sort | Rodríguez-Otero, P |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9011766 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90117662022-04-18 P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY Rodríguez-Otero, P San-Miguel, J Anderson, LD Lonial, S Truppel-Hartmann, A Sanford, J Rowe, E Campbell, TB Munshi, N Hemasphere Poster Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9011766/ http://dx.doi.org/10.1097/01.HS9.0000829656.69351.86 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Poster Rodríguez-Otero, P San-Miguel, J Anderson, LD Lonial, S Truppel-Hartmann, A Sanford, J Rowe, E Campbell, TB Munshi, N P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY |
| title | P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY |
| title_full | P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY |
| title_fullStr | P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY |
| title_full_unstemmed | P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY |
| title_short | P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY |
| title_sort | p21: subsequent anti-myeloma therapy after idecabtagene vicleucel (ide-cel, bb2121) treatment in patients with relapsed/refractory multiple myeloma from the karmma study |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011766/ http://dx.doi.org/10.1097/01.HS9.0000829656.69351.86 |
| work_keys_str_mv | AT rodriguezoterop p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy AT sanmiguelj p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy AT andersonld p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy AT lonials p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy AT truppelhartmanna p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy AT sanfordj p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy AT rowee p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy AT campbelltb p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy AT munshin p21subsequentantimyelomatherapyafteridecabtagenevicleucelidecelbb2121treatmentinpatientswithrelapsedrefractorymultiplemyelomafromthekarmmastudy |